Acquisition provides opportunity to develop cladribine in generalized Myasthenia Gravis (gMG) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
Ichnos will receive an upfront payment of Euro 20.8 million as well as additional development and commercial milestone payments and tiered royalties based upon future global sales
It is a novel oral NLRP3 inflammasome inhibitor
The Institute of Pulmonology Medical Research & Development organised a symposium on early management of Covid-19
This further adds to Biocon’s portfolio of vertically integrated complex drug products
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.
The rise in cases amongst the young is a cause for concern. A few specialists gave us a perspective on the issue
Cortrophin gel is purified corticotropin (ACTH), an important treatment option for patients struggling with certain chronic autoimmune disorders. It acquired the NDA for cortrophin gel from Merck & Co. in 2016
Moderate-to-severe plaque psoriasis affects about 35 per cent of patients. A key challenge is that many treatments stop working overtime and symptoms return
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
